Detalles de la búsqueda
1.
Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050.
J Pharmacol Exp Ther
; 356(2): 260-6, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26628406
2.
Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach.
Pharm Res
; 32(6): 1864-83, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25446771
3.
Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study.
Eur J Clin Pharmacol
; 68(3): 239-47, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21881887
4.
Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension.
CPT Pharmacometrics Syst Pharmacol
; 11(2): 173-184, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34800000
5.
Living with Polyneuropathy Organomegaly Endocrinopathy Monoclonal gammopathy Skin changes (POEMS) syndrome: a case study of healthcare experiences and quality of life.
Disabil Rehabil
; 43(17): 2502-2510, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838877
6.
Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
J Clin Pharmacol
; 60(7): 915-930, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32080863
7.
Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions.
Clin Pharmacol Ther
; 107(1): 246-256, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31356678
8.
Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion.
CPT Pharmacometrics Syst Pharmacol
; 8(9): 664-675, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31250974
9.
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.
Clin Pharmacol Ther
; 104(1): 88-110, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29315504
10.
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.
J Clin Pharmacol
; 47(2): 175-86, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17244768
11.
Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease.
J Clin Pharmacol
; 57(6): 739-746, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28144958
12.
Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.
J Clin Pharmacol
; 54(9): 968-78, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24619932
13.
A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins.
CPT Pharmacometrics Syst Pharmacol
; 8(11): 773-776, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31529677
14.
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics.
Cancer Manag Res
; 3: 157-75, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21625399
15.
A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates.
Drug Metab Pharmacokinet
; 24(1): 53-75, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19252336
16.
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
J Clin Oncol
; 27(10): 1660-6, 2009 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19237630
17.
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.
Br J Clin Pharmacol
; 64(1): 14-26, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17298479
Resultados
1 -
17
de 17
1
Próxima >
>>